Depression (mood)

INB Facilitates $12,500 Donation to Moving Pillsbury Forward

Retrieved on: 
Thursday, January 25, 2024

SPRINGFIELD, Ill., Jan. 25, 2024 /PRNewswire/ -- INB recently facilitated a $12,500 donation to Moving Pillsbury Forward (MPF), a not-for-profit organization dedicated to revitalizing the former Pillsbury Mills property on Springfield's north end.

Key Points: 
  • SPRINGFIELD, Ill., Jan. 25, 2024 /PRNewswire/ -- INB recently facilitated a $12,500 donation to Moving Pillsbury Forward (MPF), a not-for-profit organization dedicated to revitalizing the former Pillsbury Mills property on Springfield's north end.
  • "When we started, the situation looked hopeless, but all of us agreed that hopeless is not acceptable," says Chris Richmond, president of Moving Pillsbury Forward (MPF).
  • INB recognized MPF's commitment to making the community a better place and recommended them for the donation.
  • For more information on Moving Pillsbury Forward and their project, including historical documents such as employee newsletters, please visit the website, pillsburyproject.org .

Hopelessness about the future is a key reason some Black young adults consider suicide, new study finds

Retrieved on: 
Thursday, April 20, 2023

The big idea

Key Points: 
  • The big idea
    Feeling hopeless about the future is one of the primary reasons Black young adults consider suicide.
  • The study analyzed survey responses from 264 Black young adults between the ages of 18 and 30.
  • This new study, however, builds upon my earlier research by examining some of the specific reasons Black young adults consider suicide.
  • In my study, the primary reasons Black young adults consider suicide could be grouped into three main categories.

Gedeon Richter: Cariprazine demonstrates broad-spectrum antidepressant effects across different patient populations

Retrieved on: 
Wednesday, March 29, 2023

Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.

Key Points: 
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Another poster highlighted the increasing need for gathering real-world data in order to understand how the drug works in heterogeneous patient populations, therefore complementing the knowledge gained from clinical trials.
  • The 3rd poster provided details on the examination of the therapeutic reference range (TRR) for cariprazine 1.5 mg/day to 6 mg/day in schizophrenia studies.

THE JOURNAL OF MEDICAL INTERNET RESEARCH | CHATBOT CONVERSATIONS DURING COVID-19: TOPIC MODELING AND SENTIMENT ANALYSIS

Retrieved on: 
Wednesday, March 8, 2023

TORONTO and PHILADELPHIA, March 8, 2023 /PRNewswire/ -- JMIR Publications published "User-Chatbot Conversations During the COVID-19 Pandemic: A Study Based on Topic Modeling and Sentiment Analysis" in the Journal of Medical Internet Research, which mentions that chatbots became a promising tool to support public health initiatives during the COVID-19 pandemic.

Key Points: 
  • This study examined the COVID-19 pandemic-related topics online users discussed with a commercially available chatbot and compared the sentiment expressed by users from five culturally different countries.
  • They also found cultural differences, with users in the United States using more negative words compared to users in Asia when talking about COVID-19.
  • This work examined user-chatbot interactions on a live platform and provides insights into people's informational and emotional needs during a global health crisis.
  • Its flagship journal, the Journal of Medical Internet Research , is the leading digital health journal globally in content breadth and visibility, and it is the largest journal in the medical informatics field.

Louis L. Holtz, Legendary College Football Coach, to Receive 2023 Horatio Alger Award

Retrieved on: 
Wednesday, January 18, 2023

WASHINGTON, Jan. 18, 2023 /PRNewswire/ -- Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through higher education, today announced that Louis L. Holtz, legendary football coach and analyst, has been selected for membership in this prestigious organization. Mr. Holtz joins 12 other exceptional business, civic and cultural leaders from across North America in receiving 2023 honors. For 76 years, the Horatio Alger Award has been annually bestowed upon esteemed individuals who have succeeded despite facing adversities, and who have remained committed to education and charitable efforts in their communities. 

Key Points: 
  • Mr. Holtz made his NFL debut serving briefly as head coach of the New York Jets in 1976 before returning to college football.
  • "Each year, it is our utmost honor to present outstanding leaders who have displayed extraordinary perseverance in overcoming challenges with the Horatio Alger Award," said James F. Dicke II, chairman, Horatio Alger Association and 2015 Horatio Alger Award recipient.
  • Mr. Holtz and the Member Class of 2023 will be formally inducted into the Association during the Horatio Alger Award Induction Ceremonies in Washington, D.C. from March 30 through April 1, 2023.
  • For more information about Horatio Alger Association and its Member Class of 2023, please visit www.horatioalger.org and follow the organization on Facebook , Twitter and Instagram .

Cintas Corporation Releases its 2022 ESG Report

Retrieved on: 
Wednesday, January 18, 2023

Cintas Corporation (Nasdaq: CTAS) today published its 2022 Environmental, Social and Governance (ESG) Report, which details the company’s ESG Journey, performance and initiatives from the last fiscal year.

Key Points: 
  • Cintas Corporation (Nasdaq: CTAS) today published its 2022 Environmental, Social and Governance (ESG) Report, which details the company’s ESG Journey, performance and initiatives from the last fiscal year.
  • View the full release here: https://www.businesswire.com/news/home/20230118005158/en/
    Cintas Corporation today published its 2022 ESG Report, which details the company’s ESG Journey, performance and initiatives from the fiscal year that ran June 1, 2021 to May 31, 2022.
  • (Graphic: Business Wire)
    Cintas’ 2022 ESG Report is the company’s third such report and covers the company’s fiscal year 2022 (FY’22), which ended May 31, 2022.
  • For more information about Cintas’ ESG activities and its origins in sustainable business, visit cintas.com/esg .

Webb Estes Promoted to President and Chief Operating Officer of Estes Express Lines

Retrieved on: 
Tuesday, January 10, 2023

RICHMOND, Va., Jan. 10, 2023 /PRNewswire/ -- Estes Express Lines, North America's largest, privately owned freight carrier, has announced the promotion of Vice President of Process Improvement Webb Estes to president and chief operating officer (COO), effective today, January 10. Webb represents the fourth generation of the Estes family to lead the company, which was founded in 1931.

Key Points: 
  • Rob Estes remains Estes' Chairman of the Board and CEO, while Billy Hupp transitions to Vice Chairman of the Board and Corporate Executive Vice President
    RICHMOND, Va., Jan. 10, 2023 /PRNewswire/ -- Estes Express Lines, North America's largest, privately owned freight carrier, has announced the promotion of Vice President of Process Improvement Webb Estes to president and chief operating officer (COO), effective today, January 10.
  • Webb represents the fourth generation of the Estes family to lead the company, which was founded in 1931.
  • Rob Estes, formerly the company's president and CEO, will continue his duties as chairman of the board and chief executive officer.
  • Vice President and COO Billy Hupp has transitioned to the role of vice president of the board and corporate executive vice president.

Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023

The "Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The publisher's clinical trial report, "Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update' provides an overview of Treatment Resistant Depression Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Treatment Resistant Depression.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression

Retrieved on: 
Wednesday, December 21, 2022

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that it had initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression (TRD).

Key Points: 
  • Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that it had initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression (TRD).
  • Depression affects around 280 million people around the world , but 30% of those living with the condition are resistant to available antidepressant medications , meaning there is an urgent need for more effective treatments.
  • Patients will be followed for 12 weeks after initial dosing, with safety, pharmacokinetic and efficacy assessments conducted at multiple points throughout that period.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “Conditions like Treatment Resistant Depression have a devastating effect on people around the world, but they are sadly underserved when it comes to treatment opportunities.

Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Retrieved on: 
Monday, December 19, 2022

Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Key Points: 
  • Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
    clinical trial report, “Treatment Resistant Depression Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update" provides an overview of Treatment Resistant Depression Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Treatment Resistant Depression.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.